SCHEMBL1876155

SCHEMBL1876155

CN(C)Cc1cc(CO)cc(CO)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TSHR P16473 2/20 0.48
GAA P10253 2/20 0.48
LMNA P02545 2/20 0.48
GSR P00390 1/20 0.48
CYP2C9 P11712 1/20 0.48
ALOX15 P16050 1/20 0.48
HSD17B10 Q99714 1/20 0.48
HRH3 Q9Y5N1 2/20 0.44
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
THRB P10828 1/20 0.42
G6PD P11413 1/20 0.42
PABPC1 P11940 1/20 0.42
KMT2A Q03164 1/20 0.42
HKDC1 Q2TB90 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23656146 0.91 ALDH1A1 (0.42) ALDH1A1TSHRGAALMNAGSR
SCHEMBL6122351 0.89 CYP4F2 (0.44) ALDH1A1TSHRGAALMNAGSR
SCHEMBL6121987 0.89 ALDH1A1 (0.41) ALDH1A1TSHRGAALMNAGSR
SCHEMBL23794324 0.89 ALDH1A1 (0.41) ALDH1A1TSHRGAALMNAGSR
SCHEMBL2528801 0.86 ALDH1A1 (0.55) ALDH1A1TSHRGAALMNAGSR
SCHEMBL23656263 0.85 LMNA (0.39) ALDH1A1TSHRGAALMNAGSR
SCHEMBL12263642 0.84 CYP2C9 (0.42) ALDH1A1TSHRGAALMNAGSR
SCHEMBL2646040 0.81 ALDH1A1 (0.54) ALDH1A1TSHRHRH3NOS1CHRNB2
SCHEMBL2397177 0.80 CYP4A11 (0.44) ALDH1A1TSHRGAALMNAHSD17B10
SCHEMBL5126585 0.79 HRH3 (0.64) ALDH1A1TSHRGAALMNAHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3608308-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-07-21 EP disclosed
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-10-06 US disclosed
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-10-06 US disclosed
US-10729775-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-08-04 US disclosed
EP-3608308-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2020-02-12 EP disclosed
EP-2964608-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2019-08-28 EP disclosed
EP-2964608-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2019-08-28 EP disclosed
US-20180369386-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2018-12-27 US disclosed
US-10124065-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2018-11-13 US disclosed
US-20170196979-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2017-07-13 US disclosed
US-20140303232-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-10-09 US disclosed
WO-2014136086-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-09-12 WO disclosed
US-8796300-B2 Therapeutic compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-08-05 US disclosed
US-8796300-B2 Therapeutic compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-08-05 US disclosed
US-8796300-B2 Therapeutic compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-08-05 US disclosed
US-20120238595-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2012-09-20 US disclosed
US-20120238595-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2012-09-20 US disclosed
US-20120238595-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2012-09-20 US disclosed
EP-2496704-A1 THERAPEUTIC COMPOUNDS Rutgers, The State University of New Jersey (US) 2012-09-12 EP disclosed
WO-2011057126-A1 THERAPEUTIC COMPOUNDS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238595-A1 THERAPEUTIC COMPOUNDS CCNY, MKI67, MCL1 ALDH1A1 1237/4885TSHR 1681/4885GAA 867/4885
US-10124065-B2 Lipids and lipid compositions for the delivery of active agents LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885TSHR 1112/4885GAA 1423/4885
US-20180369386-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885TSHR 1112/4885GAA 1423/4885
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885TSHR 1112/4885GAA 1423/4885
US-20140303232-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885TSHR 1112/4885GAA 1423/4885
US-10729775-B2 Lipids and lipid compositions for the delivery of active agents LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885TSHR 1112/4885GAA 1423/4885
US-20170196979-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 ALDH1A1 2488/4885TSHR 1112/4885GAA 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.